We conclude that resveratrol does not change lipid profile concentration .
A : Meta‐ analysis of the effect of resveratrol supplementation on total cholesterol .
B : Meta‐ analysis of the effect of resveratrol supplementation on low‐density lipoprotein .
C : Meta‐ analysis of the effect of resveratrol supplementation on high‐density lipoprotein .
D : Meta‐ analysis of the effect of resveratrol supplementation on triglyceride after removing the study by Zortea et al. & NA ; Despite the notion that resveratrol can significantly reduce plasma lipids , the result of r and omized clinical trials ( RCTs ) on resveratrol effect and the serum lipid profile are contradictory .
Our objective was to conduct a systematic review and meta‐ analysis on r and omized clinical trials ( RCTs ) and assess the effect of resveratrol on lipids .
Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial.
CONTEXT Polycystic ovary syndrome ( PCOS ) is the most common endocrinopathy affecting women of reproductive age . Hyper and rogenism is the central feature of PCOS . Studies on isolated ovarian theca-interstitial cells suggest that resveratrol , a natural polyphenol , reduces and rogen production . OBJECTIVE This study was design ed to evaluate endocrine and metabolic effects of resveratrol on PCOS . DESIGN AND SETTING This was a r and omized ( 1:1 ) double-blind , placebo-controlled trial that evaluated the effects of resveratrol over a period of 3 months in an academic hospital . PATIENTS AND OTHER PARTICIPANTS Subjects with PCOS were identified according to the Rotterdam criteria . Thirty-four subjects were enrolled and 30 subjects completed the trial . Evaluations were performed at baseline and repeated after 3 months of treatment . INTERVENTION Resveratrol ( 1,500 mg p.o . ) or placebo were administered daily . MAIN OUTCOME MEASURE Primary outcome was the change in the serum total T. RESULTS Resveratrol treatment led to a significant decrease of total T by 23.1 % ( P = .01 ) . In parallel , resveratrol induced a 22.2 % decrease of dehydroepi and rosterone sulfate ( P = .01 ) , a decrease of fasting insulin level by 31.8 % ( P = .007 ) and an increase of the Insulin Sensitivity Index ( Matsuda and DeFronzo ) by 66.3 % ( P = .04 ) . Levels of gonadotropins , the lipid profile as well as markers of inflammation and endothelial function were not significantly altered . CONCLUSIONS Resveratrol significantly reduced ovarian and adrenal and rogens . This effect may be , at least in part , related to an improvement of insulin sensitivity and a decline of insulin level
We conclude that resveratrol does not change lipid profile concentration .
A : Meta‐ analysis of the effect of resveratrol supplementation on total cholesterol .
B : Meta‐ analysis of the effect of resveratrol supplementation on low‐density lipoprotein .
C : Meta‐ analysis of the effect of resveratrol supplementation on high‐density lipoprotein .
D : Meta‐ analysis of the effect of resveratrol supplementation on triglyceride after removing the study by Zortea et al. & NA ; Despite the notion that resveratrol can significantly reduce plasma lipids , the result of r and omized clinical trials ( RCTs ) on resveratrol effect and the serum lipid profile are contradictory .
Our objective was to conduct a systematic review and meta‐ analysis on r and omized clinical trials ( RCTs ) and assess the effect of resveratrol on lipids .